- Home
- VTYX vs SCPH Comparison
VTYX vs SCPH Comparison
Compare VTYX & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- SCPH
- Stock Information
- Founded
- VTYX 2018
- SCPH 2013
- Country
- VTYX United States
- SCPH United States
- Employees
- VTYX N/A
- SCPH N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- VTYX Health Care
- SCPH Health Care
- Exchange
- VTYX Nasdaq
- SCPH Nasdaq
- Market Cap
- VTYX 154.9M
- SCPH 173.6M
- IPO Year
- VTYX 2021
- SCPH 2017
- Fundamental
- Price
- VTYX $2.74
- SCPH $4.85
- Analyst Decision
- VTYX Buy
- SCPH Strong Buy
- Analyst Count
- VTYX 2
- SCPH 3
- Target Price
- VTYX $9.00
- SCPH $14.00
- AVG Volume (30 Days)
- VTYX 776.8K
- SCPH 322.0K
- Earning Date
- VTYX 08-07-2025
- SCPH 08-07-2025
- Dividend Yield
- VTYX N/A
- SCPH N/A
- EPS Growth
- VTYX N/A
- SCPH N/A
- EPS
- VTYX N/A
- SCPH N/A
- Revenue
- VTYX N/A
- SCPH $49,969,000.00
- Revenue This Year
- VTYX N/A
- SCPH $108.95
- Revenue Next Year
- VTYX N/A
- SCPH $73.83
- P/E Ratio
- VTYX N/A
- SCPH N/A
- Revenue Growth
- VTYX N/A
- SCPH 107.79
- 52 Week Low
- VTYX $0.78
- SCPH $1.94
- 52 Week High
- VTYX $3.39
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- VTYX 51.07
- SCPH 51.56
- Support Level
- VTYX $2.38
- SCPH $4.33
- Resistance Level
- VTYX $3.05
- SCPH $4.82
- Average True Range (ATR)
- VTYX 0.22
- SCPH 0.35
- MACD
- VTYX -0.02
- SCPH -0.07
- Stochastic Oscillator
- VTYX 55.15
- SCPH 49.55
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.